This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 53/5/775    most recent HYPERTENSIONAHA.108.126524v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mukaddam-Daher, S. Articles by Tardif, J.-C. Search for Related Content PubMed PubMed Citation Articles by Mukaddam-Daher, S. Articles by Tardif, J.-C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines High Blood Pressure Hazardous Substances DB THIOPHENE Related Collections Cardiovascular Pharmacology ACE/Angiotension receptors Animal models of human disease Apoptosis Growth factors/cytokines Hypertrophy Echocardiography

(Hypertension. 2009;53:775.)
© 2009 American Heart Association, Inc.

Original Articles

Hemodynamic and Cardiac Effects of Chronic Eprosartan and Moxonidine Therapy in Stroke-Prone Spontaneously Hypertensive Rats

Suhayla Mukaddam-Daher; Ahmed Menaouar; Pierre-Alexandre Paquette; Marek Jankowski; Jolanta Gutkowska; Marc-Antoine Gillis; Yan-Fen Shi; Angelo Calderone; Jean-Claude Tardif

From the University of Montreal Hospital Research Center (CRCHUM) (S.M-D., A.M., P-A.P., M.J., J.G.); and Montreal Heart Institute (M-A.G., Y-F.S., A.C., J-C.T.), Departments of Medicine and Pharmacology, University of Montreal, Montreal, Quebec, Canada.

Correspondence to Suhayla Mukaddam-Daher, CRCHUM - St Luc (A-301), 264 Rene Levesque East, Montreal, Quebec, Canada, H2X 1P1. E-mail suhayla.mukaddam-daher{at}umontreal.ca

The renin-angiotensin and sympathetic nervous systems play critical interlinked roles in the development of left ventricular hypertrophy, fibrosis, and dysfunction. These studies investigated the hemodynamic and cardiac effects of monoblockade and coblockade of renin-angiotensin and sympathetic nervous systems. Stroke-prone spontaneously hypertensive rats (16 weeks old; male; n=12 per group) received the sympatholytic imidazoline compound, moxonidine (2.4 mg/kg per day); the angiotensin-receptor blocker eprosartan (30 mg/kg per day), separately or in combination; or saline vehicle for 8 weeks, SC, via osmotic minipumps. Blood pressure and heart rate were continuously measured by radiotelemetry. After 8 weeks, in vivo cardiac function and structure were measured by transthoracic echocardiography and a Millar conductance catheter, and the rats were then euthanized and blood and heart ventricles collected for various determinations. Compared with vehicle, the subhypotensive dose of moxonidine resulted in lower (P<0.01) heart rate, left ventricular hypertrophy, cardiomyocyte cross-sectional area, interleukin 1β, tumor necrosis factor-, and mRNA for natriuretic peptides. Eprosartan reduced pressure (P<0.01), as well as extracellular signal–regulated kinase (ERK) 44 phosphorylation, Bax/Bcl-2, and collagen I/III, and improved left ventricular diastolic function (P<0.03). Combined treatment resulted in greater reductions in blood pressure, heart rate, left ventricular hypertrophy, collagen I/III, and inhibited inducible NO synthase and increased endothelial NO synthase phosphorylation, as well as reduced left ventricular anterior wall thickness, without altering the other parameters. Thus, in advanced hypertension complicated with cardiac fibrosis, sympathetic inhibition and angiotensin II blockade resulted in greater reduction in blood pressure and heart rate, inhibition of inflammation, and improved left ventricular pathology but did not add to the benefits of angiotensin II blockade on cardiac function.

Key Words: hypertension • hypertrophy • hemodynamics • natriuretic peptides • moxonidine • eprosartan